DP
ENTA icon

Diadema Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Diadema Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64,952
Closed -$820K – 163
2026
Q1 		$820K Sell
64,952
-186
-0.3% -$2.49K 0.14% 90
2025
Q4 		$1.03M Buy
+65,138
New +$827K 0.18% 91

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Diadema Partners's ENTA Position: Q2 2026 in Review

Diadema Partners sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 64,952 shares — an estimated $820K sold.

Diadema Partners first reported a position in ENTA in Q4 2025 and held it in 2 quarters. The position peaked at $1.03M in Q4 2025. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Diadema Partners reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Diadema Partners sold 64,952 Enanta Pharmaceuticals shares in Q2 2026, an estimated $820K.
  • Diadema Partners first reported a position in Enanta Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Diadema Partners's Enanta Pharmaceuticals position peaked at $1.03M in Q4 2025.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.